HER-2 positive
HER-2 positive
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
trastuzumab
Sensitive: A2 - Guideline
|
PD-L1 overexpression
PD-L1 overexpression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
PD1 inhibitor
Sensitive: B - Late Trials
|
PD-L1 overexpression
PD-L1 overexpression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
PD-L1 inhibitor
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
pembrolizumab + trastuzumab
Sensitive: C1 - Off-label
|
HER-2 positive
HER-2 positive
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
pembrolizumab
Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
TP53 mutation
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
Immunotherapy
Resistant: C3 – Early Trials
|
TET1 mutation
TET1 mutation
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
Immunotherapy
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
ZW25
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
Immunotherapy
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
RC48
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
tislelizumab
Sensitive: C3 – Early Trials
|
FGFR2 amplification
FGFR2 amplification
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
ABSK-091
Sensitive: C3 – Early Trials
|
MET amplification
MET amplification
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
crizotinib
Sensitive: C3 – Early Trials
|
TGFB1 elevation
TGFB1 elevation
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
M7824
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
ZW25
Sensitive: C3 – Early Trials
|
MET amplification
MET amplification
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
afatinib
Resistant: C3 – Early Trials
|
EGFR amplification + ERBB2 amplification
EGFR amplification + ERBB2 amplification
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
afatinib
Sensitive: C3 – Early Trials
|
CFB overexpression
CFB overexpression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
sunitinib
Sensitive: C3 – Early Trials
|
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
sunitinib
Sensitive: C3 – Early Trials
|
HER-2 positive
HER-2 positive
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
|
POLE mutation
POLE mutation
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
Immunotherapy
Sensitive: C3 – Early Trials
|
POLD1 mutation
POLD1 mutation
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
Immunotherapy
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
PD-L1 inhibitor
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
PD1 inhibitor
Sensitive: C3 – Early Trials
|
HER-2 mutation
HER-2 mutation
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
dasatinib
Sensitive: D – Preclinical
|
HER-2 mutation
HER-2 mutation
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
neratinib
Sensitive: D – Preclinical
|
HER-2 mutation
HER-2 mutation
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
dasatinib + neratinib
Sensitive: D – Preclinical
|
BCL2 overexpression + MCL1 overexpression
BCL2 overexpression + MCL1 overexpression
|
GastroEsophageal Cancer
GastroEsophageal Cancer
|
AT 101
Sensitive: D – Preclinical
|
